Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.80 |
| ▸ | CA1 | P00915 | 3/20 | 0.80 |
| ▸ | CA2 | P00918 | 3/20 | 0.80 |
| ▸ | CA9 | Q16790 | 3/20 | 0.80 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | FAAH | O00519 | 3/20 | 0.58 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.55 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | GPR183 | P32249 | 1/20 | 0.52 |
| ▸ | LSS | P48449 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10502128 | 0.85 | POLB (0.70) | CA12CA1CA2CA9POLB | |
| Hydrochloric Acid SCHEMBL10502730 | 0.82 | POLB (0.67) | CA12CA1CA2CA9POLB | |
| SCHEMBL3923607 | 0.81 | CA12 (0.60) | CA12CA1CA2CA9FAAH | |
| SCHEMBL7369921 | 0.80 | ALDH1A1 (0.73) | POLBFAAHAKR1C3CACNA1GGPR183 | |
| SCHEMBL10502122 | 0.79 | POLB (0.63) | CA12CA1CA2CA9POLB | |
| SCHEMBL3918942 | 0.79 | CA12 (0.57) | CA12CA1CA2CA9FAAH | |
| Hydrochloric Acid SCHEMBL10503178 | 0.78 | POLB (0.62) | CA12CA1CA2CA9POLB | |
| SCHEMBL15868592 | 0.78 | PKM (0.58) | CA12CA1CA2CA9POLB | |
| SCHEMBL10689422 | 0.78 | HTR7 (0.74) | POLBFAAHAKR1C3CACNA1GGPR183 | |
| SCHEMBL2931705 | 0.77 | AKR1C3 (0.65) | POLBFAAHAKR1C3GPR183LSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119471-A1 | Piperazine urea derivatives for the treatment of endometriosis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-05-22 | — | — | US | disclosed |
| US-7268140-B2 | Piperazine derivatives and their use as anti-inflammatory agents | SCHERING AG (DE) | 2007-09-11 | — | — | US | disclosed |
| EP-1727526-A2 | PIPERAZINE UREA DERIVATIVES FOR THE TREATMENT OF ENDOMETRIOSIS | Schering Aktiengesellschaft (DE) | 2006-12-06 | — | — | EP | disclosed |
| US-20060135487-A1 | Piperazine derivatives and their use as anti-inflammatory agents | BAUMAN JOHN G | 2006-06-22 | — | — | US | disclosed |
| US-6977258-B2 | Piperazine derivatives and their use as anti-inflammatory agents | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-12-20 | — | — | US | disclosed |
| US-6972290-B2 | Piperazine derivatives and their use as anti-inflammatory agents | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-12-06 | — | — | US | disclosed |
| WO-2005079769-A2 | PIPERAZINE DERIVATIVES FOR THE TREATMENT OF ENDOMETRIOSIS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-09-01 | — | — | WO | disclosed |
| US-20030158205-A1 | Piperazine derivatives and their use as anti-inflammatory agents | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-08-21 | — | — | US | disclosed |
| US-20030139425-A1 | Piperazine derivatives and their use as anti-inflammatory agents | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-07-24 | — | — | US | disclosed |
| US-6573266-B1 | Compounds used for treating multitiple sclerosis and encephalomyelitis | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-06-03 | — | — | US | disclosed |
| US-6555537-B2 | Inhibit activity of chemokines, macrophage inflammatory protein-1 (MIP-1 alpha) and RANTES; 1-((4-chlorophenoxy)methyl)-carbonyl-2-methyl-4-(4-fluorobenzyl)piperazine for example | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-04-29 | — | — | US | disclosed |
| US-6541476-B1 | Treating multiple sclerosis or encephalomyelitis in a human | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-04-01 | — | — | US | disclosed |
| US-6534509-B1 | Derivatives are useful as anti-inflammatory agents. This invention is also directed to pharmacetutical compostions for inflammation | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-03-18 | — | — | US | disclosed |
| EP-0988292-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | SCHERING AG (DE) | 2003-02-12 | — | — | EP | disclosed |
| US-20020177598-A1 | Piperazine derivatives and their use as anti-inflammatory agents | SCHERING AKTIENGSCHELLSCHAFT | 2002-11-28 | — | — | US | disclosed |
| EP-1254899-A2 | Piperazine derivatives and their use as anti-inflammatory agents | Schering Aktiengesellschaft (DE) | 2002-11-06 | — | — | EP | disclosed |
| US-6207665-B1 | TO TREAT INFLAMMATORY DISORDERS IN HUMANS | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-03-27 | — | — | US | disclosed |
| EP-0988292-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-03-29 | — | — | EP | disclosed |
| WO-1998056771-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139425-A1 | Piperazine derivatives and their use as anti-inflammatory agents | IL5, PTGES2, PTGES | CA12 4297/4885CA1 4558/4885CA2 2886/4885 |
| US-20060135487-A1 | Piperazine derivatives and their use as anti-inflammatory agents | IL5, PTGES2, PTGES | CA12 4297/4885CA1 4558/4885CA2 2886/4885 |
| US-20020177598-A1 | Piperazine derivatives and their use as anti-inflammatory agents | IL5, PTGES2, PTGES | CA12 4297/4885CA1 4558/4885CA2 2886/4885 |
| US-20030158205-A1 | Piperazine derivatives and their use as anti-inflammatory agents | IL5, PTGES2, PTGES | CA12 4297/4885CA1 4558/4885CA2 2886/4885 |
| US-20080119471-A1 | Piperazine urea derivatives for the treatment of endometriosis | ESR2, GPER1, SLC14A1 | CA12 3712/4885CA1 3517/4885CA2 3996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.